Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...

Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary - Weeks after the monumental ...

Nathan Congdon, MD, highlights a recent study showing how virtual mentor-mentee relationships through Orbis' free ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has completed its acquisition of Ambry Genetics, a ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has completed its acquisition of Ambry Genetics, a ...

Can supplementing with vitamins and minerals protect your eye health? Learn more about the role of nutrients in age-related ...

Avant Technologies Inc shares O.AVAI are trading -0.07 at $0.64.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Beyond Stargate's big players, a growing number of innovators have been revolutionizing healthcare by making recent ...